Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance.

"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsMZ received grants for research activities from Gilead Sciences, Merck Sharp and Dohme, Theratechnologies and ViiV Healthcare and personal fees for advisory boards and training activities from Gilead Sciences, GlaxoSmithKline, Merck Sharp and Dohme, Theratechnologies and ViiV Healthcare outside the submitted work. RWS received personal fees for advisory boards and training activities from Gilead Sciences and GlaxoSmithKline. We declare no competing interests. Competing interests MZ received grants for research activities from Gilead Sciences, Merck Sharp and Dohme, Theratechnologies and ViiV Healthcare and personal fees for advisory boards and training activities from Gilead Sciences, GlaxoSmithKline, Merck Sharp and Dohme, Theratechnologies and ViiV Healthcare outside the submitted work. RWS received personal fees for advisory boards and training activities from Gilead Sciences and GlaxoSmithKline. We declare no competing interests."

"Funding SR and RWS were supported in part by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institute of Health (NIH) (award number AI136618)."